F8 and acquired hemophilia: Hyate:C, or plasma-derived porcine fVIII, ceased from being administered to hemophilia A patients in 2005 due to concerns over porcine viral contamination [42], but a recombinant version of porcine fVIII has recently been approved for the treatment of hemophilia A patients with inhibitor as well as acquired hemophilia patients [43, 44].